Breaking Finance News

Abbott Laboratories (NYSE:ABT) has been upgraded to B in a statement by TheStreet earlier today.

TheStreet has upgraded Abbott Laboratories (NYSE:ABT) to B in a statement released on 7/3/2017.

On 7/04/2017, Wells Fargo Company released a statement for Abbott Laboratories (NYSE:ABT) bumped up the target price from $47.50 to $54.00 that suggested an upside of 0.11%.

Boasting a price of $48.40, Abbott Laboratories (NYSE:ABT) traded 1.00% higher on the day. With the last stock price close up 6.32% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the date range. ABT has recorded a 50-day average of $49.09 and a two hundred day average of $45.65. Trade Volume was down over the average, with 3,978,902 shares of ABT changing hands under the typical 6,131,510

Recent Performance Chart

Abbott Laboratories (NYSE:ABT)

Abbott Laboratories has PE ratio of 67.98 with a one year low of $37.38 and a one year high of $51.13 and has a market capitalization of $0.

A total of 15 analysts have released a report on Abbott Laboratories. Six analysts rating the company a strong buy, eight analysts rating the company a buy, six analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $46.73.

General Company Details For Abbott Laboratories (NYSE:ABT)

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.